Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-577.5%-566pp-11.2%-24.4pp13.2%-6.9pp20.2%+0.1pp20%+297pp
Net margin-529.2%-525pp-3.7%-23.5pp19.7%-6.5pp26.3%-0.1pp26.3%+270pp
EBITDA margin-572.1%-562pp-10.2%-24.4pp14.1%-7.0pp21.1%0.0pp21.1%+292pp
Returns
Return on equity-45.6%-43.2pp-2.4%-17.4pp15%-3.2pp18.2%-2.3pp20.5%+66.3pp
Return on assets-39.9%-37.9pp-2%-14.4pp12.4%-2.7pp15.2%-1.3pp16.4%+52.0pp
Return on invested capital-114.4%
Efficiency
Asset turnover0.1×-0.5×0.5×-0.1×0.6×+0.1×0.6×0.0×0.6×+0.5×
Liquidity
Current ratio+3.7×5.3×-1.2×6.5×-0.5×-1.4×8.4×+2.6×
Quick ratio+3.7×5.3×-1.2×6.5×-0.5×-1.4×8.4×+2.6×
Cash ratio3.8×+2.4×1.5×-0.5×-0.6×2.6×-3.5×6.2×+3.0×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Interest coverage-13×-11.5×-1.5×-3.6×2.1×-1.0×3.1×+0.1×2.9×+10.9×
Per Share
Book value per share$6.26+5.2%$5.95+13.2%$5.26-8.4%$5.74-2.6%$5.89+39.0%
Valuation
Market capitalization$1.93B+6.2%$1.81B+40.8%$1.29B+105%$628.41M+74.7%$359.62M-38.4%
Enterprise value$1.77B+2.4%$1.73B+43.7%$1.21B+127%$532.22M+486%$90.75M-80.3%
Price / sales60×+50.2×9.8×+3.6×6.3×+3.1×3.1×+1.3×1.9×-14.1×
Price / book4.9×-0.3×5.1×+1.0×4.2×+2.3×1.9×+0.8×-1.5×
EV / sales55.3×+45.9×9.4×+3.5×5.9×+3.2×2.7×+2.2×0.5×-12.1×
Earnings yield-8.8%-8.4pp-0.4%-3.5pp3.2%-5.2pp8.4%-5.6pp14%+29.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Stoke Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Stoke Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.